Pictet Asset Management Holding SA Has $396,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Pictet Asset Management Holding SA raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 19.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,678 shares of the company’s stock after acquiring an additional 761 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Axsome Therapeutics were worth $396,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AXSM. Meridian Wealth Management LLC boosted its position in shares of Axsome Therapeutics by 0.7% in the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company’s stock worth $1,791,000 after purchasing an additional 150 shares during the last quarter. Arizona State Retirement System boosted its holdings in Axsome Therapeutics by 1.8% during the fourth quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock worth $766,000 after buying an additional 164 shares during the last quarter. Xponance Inc. grew its position in shares of Axsome Therapeutics by 11.6% during the 4th quarter. Xponance Inc. now owns 2,659 shares of the company’s stock worth $225,000 after buying an additional 277 shares during the period. KBC Group NV increased its stake in shares of Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after acquiring an additional 385 shares during the last quarter. Finally, Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $52,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.40% of the stock is owned by insiders.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $101.67 on Thursday. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The stock has a 50-day moving average price of $120.05 and a 200-day moving average price of $101.90. The company has a market cap of $4.96 billion, a PE ratio of -16.97 and a beta of 0.88. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. As a group, equities analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AXSM. Robert W. Baird lifted their price target on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Axsome Therapeutics in a report on Thursday, April 3rd. Jefferies Financial Group initiated coverage on Axsome Therapeutics in a report on Monday. They issued a “buy” rating and a $200.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $153.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Finally, William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $169.80.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.